Tasimelteon vs Ramelteon — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Melatonin Receptor Agonist

Tasimelteon

Brand: Hetlioz

First FDA approval: 2014-04-04

Melatonin Receptor Agonist

Ramelteon

Brand: Rozerem

First FDA approval: 2005-07-22

Lowest NADACAcquisition cost floor across all NDCs

$400.17Per unit

$0.717Per unit

Average NADACAcross all dosage forms and strengths

$400.17Up to $400.17

$1.59Up to $12.45

Generic manufacturersActive ANDA holders — FDA Orange Book

33 total ANDAs filed

99 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$143.5MFull year

$37.4MFull year

Part D claims (CY24)Total fills, all strengths

6K1K beneficiaries

359K119K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$22,571Per claim, all NDCs

$104Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

235Substantial friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

1Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes3 manufacturers

Yes9 manufacturers